| European Case Law Identifier: | ECLI:EP:BA:2017:T076012.20171127 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 27 November 2017 | ||||||||
| Case number: | T 0760/12 | ||||||||
| Application number: | 04754499.4 | ||||||||
| IPC class: | G01N 33/74 G01N 33/68 C07K 7/08 A61K 38/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | MODULATING THE INTERACTION BETWEEN HGF BETA CHAIN AND C-MET | ||||||||
| Applicant name: | Genentech, Inc. | ||||||||
| Opponent name: | GLAXO GROUP LIMITED Millennium Pharmaceuticals, Inc. Galaxy Biotech, LLC |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Oral proceedings - held in absence of appellant Sufficiency of disclosure - (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t120760eu1.html
Date retrieved: 17 May 2021